about
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursp53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis.Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21.Are renal microgranulomas related to inflammatory tubular destruction?Measurement of quality of life in carcinoid/neuroendocrine tumours.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)A multimodal approach to the management of neuroendocrine tumour liver metastasesNeuroendocrine tumour management: a team approach.Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumoursGastrinoma (duodenal and pancreatic).How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist.ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors.Review article: the investigation and management of gastric neuroendocrine tumours.Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach.A cross-cultural convergent parallel mixed methods study of what makes a cancer-related symptom or functional health problem clinically important.ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms.ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms.Review article: the investigation and management of rectal neuroendocrine tumours.Optimized Outcomes Using a Standardized Approach for the Treatment of Patients with Carcinoid Heart Disease.A Systematic Review of Symptoms and Quality of Life Issues in Pancreatic Neuroendocrine Tumours.Acute Liver Failure in a Patient Travelling From Asia: The Other Face of the Coin of Infectious Disease.The European organization for research and treatment of cancer - satisfaction with cancer care questionnaire: revision and extended application development.Overview: the management of metastatic carcinoid tumors.Smoking, gastric secretion and inhibition by cimetidine.The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients.Effect of cimetidine and pirenzepine in combination on 24 hour intragastric acidity in subjects with previous duodenal ulcerationChanges in intestinal permeability and epithelial differentiation during inflammation in the rat.Reducing overnight secretion of acid to heal duodenal ulcers. Comparison of standard divided dose of ranitidine with a single dose administered at night.Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder.Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices.Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases.Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease.Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours.Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7).Ileo-colonic neuroendocrine tumours identified in the English bowel cancer screening programme (BCSP).Neuroendocrine Tumors.
P50
Q24685837-6CAFBBD2-5A86-4306-965B-48BD7993B2E6Q34409334-9D603A31-BCC1-40EA-BEF6-DDD10A9610C0Q34627921-22DC9459-AE60-4AA1-B2E2-B0FC00CC5734Q35587598-CCADA1AA-AA06-41F5-B4EA-CED9F2937FFAQ35624493-B5A127D4-9709-404D-8CF0-C8444FE3DB73Q35760798-065E0AFC-394F-43A2-A4EF-EDB11DC6B1C8Q35810562-B8699226-AFFF-4F6A-B739-2610F9E72C32Q36027156-E174EFED-D6F9-4C47-9112-2AD0C23AF92BQ36037071-8EE88F9A-5CCD-4313-9543-CE21DE6733D2Q36594133-50B6A09D-DB43-4E41-9977-EC566034889CQ36741116-43A168E9-AA55-45EB-8687-BAC3A6E5F07CQ36947936-1234A3E1-925E-4E2C-A09C-7D21D16A5442Q37756446-66C2B2EC-E7BD-4B49-912F-746026F98697Q38195905-38F2B8A5-5338-4B06-BFCD-6A27EAE3FF26Q38447078-A1AFD37E-0E5E-4EB7-9F2E-C8B8BD552DA2Q38600539-FD68E748-A97C-4F4C-9518-8687FFB7D275Q38686867-8825598E-51A3-4A75-BB52-41E70F1E10BFQ38702734-B84DA07F-5558-4027-A50D-17F6BB97F3A9Q38865549-4F5859A2-436F-4F9B-93C0-8A23FA4A0564Q38878614-F78AADAC-B56C-4BC2-B0EE-ED406B8F8E18Q39250779-186A51DC-CACE-43E6-85FA-CEC1705F4A54Q40038784-1E2A54EE-D0BC-4DE1-8F47-0B91CBC2418AQ40613311-41938EAD-CDD7-4EE7-B5C1-349636DB155EQ40991882-FC6EC8EB-0F49-4295-886B-23C5C424DC64Q41395979-694E0C67-D24D-457E-AA2F-E1D7112B8CDCQ41695647-47111B1F-D4B9-4766-A60B-C5C82071FFE7Q41968638-908BCF45-2D77-4DF9-8EF6-D7D201A5665BQ42027975-306E1D9E-D2C8-4493-8742-BAEBE9C9AB78Q42240612-A1D040F2-DE76-4C8E-A503-12FA854D9D8EQ42759385-516A77B4-97D6-4022-8A7D-FD4D683CD57CQ43777510-CF26F35A-EA13-47CC-BC9D-60B127343AB9Q44559988-2649F815-C462-43BF-86BA-4BA5BD184E60Q46058952-C5F3C0F4-FBF5-4DFD-9A0C-F8D247DBF63DQ46348065-CE98758A-BEDF-4EC2-A78A-59F80641EF34Q46538041-84B9BA8F-3F54-43CA-BE02-DC06494B2134Q46746466-3C20566E-2336-48B2-89D0-896BF99D7899Q47150030-1844E6EC-C2D7-4D06-ADFF-0D37E5B1571AQ47630374-64B1E9E2-D2B7-475B-89FE-735734210CF3Q49719813-578F4414-E478-41CA-A8A6-7E5BAB9840D5Q50908956-3C8EB643-EF0A-4B82-95AF-C5B1D9260F48
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John K Ramage
@ast
John K Ramage
@en
John K Ramage
@es
John K Ramage
@nl
type
label
John K Ramage
@ast
John K Ramage
@en
John K Ramage
@es
John K Ramage
@nl
altLabel
john ramage
@en
prefLabel
John K Ramage
@ast
John K Ramage
@en
John K Ramage
@es
John K Ramage
@nl
P214
P244
P106
P214
P244
nb2005016461
P31
P496
0000-0003-4824-6600
P735
P7859
lccn-nb2005016461